Control of trace metals during anti-CD38 antibody production

By adjusting the manganese concentration in the culture medium during the biosynthesis process of anti-CD38 antibodies and controlling its G1F oligosaccharide content, the antibody stability and antigenicity problems were solved, and a predictable glycosylation distribution map was achieved.

CN113015805BActive Publication Date: 2024-12-03JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980074932.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-11-13
Filing Date
2019-11-13
Publication Date
2024-12-03
Estimated Expiration
2039-11-13

AI Technical Summary

Technical Problem

The prior art is difficult to effectively control the G1F oligosaccharide content of anti-CD38 antibodies, which affects its antigenicity, in vivo clearance and stability, and the cell culture conditions are insufficient to predict the glycosylation distribution map.

Method used

By preparing a culture medium containing about 8.5 billion or less, culturing host cells encoding specific heavy chain variable regions and light chain variable regions, monitoring and regulating the concentration of manganese in the culture medium to control anti-CD38 antibodies The G1F oligosaccharide content is between 15% and 27%.

Benefits of technology

Predictable control of the G1F oligosaccharide content of anti-CD38 antibody is achieved, improving its stability and antigenicity, and ensuring consistency of product quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113015805B_ABST
    Figure CN113015805B_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods for controlling trace metals during anti-CD38 antibody production, drug substances and drug products produced using the methods, and uses of the produced drug substances and drug products.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 760,782, filed on November 13, 2018, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present disclosure relates to methods for controlling trace metals during anti-CD38 antibody production, drug substances and drug products produced using the methods, and uses of the produced drug substances and drug products.

[0004] Sequence Listing

[0005] This application contains a sequence listing submitted via EFS-Web, the entire contents of which are incorporated herein by reference. The ASCII text file created on November 2, 2018 is named JBI6023WOPCT_ST25.txt and is 91 kilobytes in size. Background Art

[0006] In the past several decades, many studies have focused on the production of recombinant proteins, such as producing monoclonal antibodies by cell culture. Although culture media containing serum or hydrolysate have been used for such cultures, chemically defined culture media have been developed to minimize the batch-to-batch variation of culture media components (Luo and Chen, Biotechnology and Bioengineering 97 (6): 1654-59, 2007). Improved understanding of cell culture has allowed the shift to chemically defined culture media without compromising product quality while maintaining relatively high vigor.

[0007] N-glycosylation during antibody production can mediate its antigenicity, in vivo clearance, stability, and Fc-mediated effector functions, and can depend on cell culture conditions. Therefore, there is a need to develop methods that can provide predictable glycosylation profiles of therapeutic antibodies obtained by cell culture in chemically defined medium. Summary of the invention

[0008] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding a heavy chain variable region (VH) of SEQ ID NO: 7 and a light chain variable region (VL) of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0009] preparing a culture medium comprising about 8.5 parts per billion (ppb) or less manganese (Mn); and

[0010] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in the culture medium prepared in step a), thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0011] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0012] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0013] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0014] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0015] preparing a culture medium comprising about 8.5 ppb or less Mn;

[0016] controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in the culture medium prepared in step a), thereby producing an anti-CD38 antibody having a G1F oligosaccharide content of between about 15% and about 27%; and

[0017] The anti-CD38 antibody is formulated as a drug product. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The various manufacturing batches are shown Correlation of (daratumumab) G0F oligosaccharide percentage (G0F%) with manganese (Mn) concentration calculated from dry powder medium (DPM). Y-axis: Mn concentration, parts per billion (ppb); X-axis: G0F%.

[0019] Figure 2 The various manufacturing batches are shown (Daratumumab) Correlation of G1F oligosaccharide percentage (G1F%) and Mn concentration calculated by DPM. Y axis: Mn concentration (ppb); X axis: G1F%.

[0020] Figure 3 The results for out-of-specification (OOS), out-of-trend (OOT) and conforming batches are shown. (Daratumumab) G0F% versus Mn concentration calculated from DPM bioreactor medium composition.

[0021] Figure 4 Shows the OOS, OOT and qualified batches (Daratumumab) G1F% versus Mn concentration calculated from DPM bioreactor medium composition.

[0022] Figure 5 shows the time variation of various production batches (Daratumumab) G1F% (indicated as G1F% in the figure) and Mn concentration.

[0023] Figure 6 Shown are the total Mn concentrations (ppb) before, during and after the OOS / OOT batch manufacturing. DETAILED DESCRIPTION

[0024] All publications, including but not limited to patents and patent applications, cited in this specification are incorporated herein by reference as if fully set forth herein.

[0025] It should be understood that the terminology used herein is for describing specific embodiments only and is not intended to be limiting. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0026] Although any methods and materials similar or equivalent to those described herein can be used in the practice of testing the present disclosure, exemplary materials and methods are described herein.In describing and claiming the present disclosure, the following terminology will be used.

[0027] definition

[0028] As used in this specification and the appended claims, the singular forms "a," "an," "the," and "said" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a cell" includes a combination of two or more cells, and so forth.

[0029] "About" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. In the context of a particular assay, result, or embodiment, unless otherwise expressly stated in the examples or elsewhere in the specification, "about" means within one standard deviation, or up to a range of 5%, whichever is greater, according to customary practice in the art.

[0030] "Antibody" refers to an immunoglobulin molecule having two heavy chains (HC) and two light chains (LC) interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region, which is divided into CH1, hinge, CH2 and CH3 regions. Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). VH and VL can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), interspersed with framework regions (FRs). Each VH and VL consists of three CDRs and four FR segments, and is arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. Antibodies include monoclonal antibodies, including mouse, human, humanized and chimeric antibodies, bispecific or multispecific antibodies. Immunoglobulins can be designated as five major species, IgA, IgD, IgE, IgG and IgM, based on the amino acid sequence of the heavy chain constant region. IgA and IgG are further subdivided into the isotypes IgAl, IgA2, IgGl, IgG2, IgG3, and IgG4.The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, kappa and lambda, based on the amino acid sequences of their constant domains.

[0031] "Antigen binding fragment" refers to a portion of an immunoglobulin molecule that retains the antigen binding properties of a parent full-length antibody. Exemplary antigen binding fragments are heavy chain complementary determining regions (HCDR) 1, 2 and / or 3, light chain complementary determining regions (LCDR) 1, 2 and / or 3, VH, VL, VH and VL, Fab, F(ab')2, Fd and Fv fragments, and domain antibodies (dAbs) consisting of one VH domain or one VL domain. The VH and VL domains can be linked together via synthetic linkers to form various types of single-chain antibody designs, in which the VH and VL domains are expressed by separate chains and the VH / VL domains are paired intramolecularly or intermolecularly to form a monovalent antigen binding site, such as a single-chain Fv (scFv) or a diabody; for example, as described in International Patent Publication WO1998 / 44001, International Patent Publication WO1988 / 01649; International Patent Publication WO1994 / 13804; International Patent Publication WO1992 / 01047.

[0032] “Biosimilar” (of an approved reference product / biologic drug) means a biological product that is highly similar to the reference product except for minor differences in clinically inactive components, and that has no clinically meaningful differences in safety, purity, and potency between the biosimilar and the reference product based on data derived from: (a) analytical studies that demonstrate that the biological product is highly similar to the reference product except for minor differences in clinically inactive components; (b) animal studies (including evaluations of toxicity); and / or (c) one or more clinical studies (including evaluations of immunogenicity and pharmacokinetics or pharmacodynamics) that are adequate to demonstrate the safety, purity, and potency of the reference product under one or more appropriate conditions of use for which the reference product is licensed, intended, and for which the biosimilar is sought. A biosimilar may be an interchangeable product that can be substituted for the reference product at the pharmacy without intervention by the prescribing health care professional. In order to meet the additional standard of "interchangeability", biosimilars should be expected to produce the same clinical results as the reference product in any given patient, and if the biosimilar is administered to an individual more than once, the risk of alternating or exchanging between the use of the biosimilar and the reference product in terms of safety or efficacy reduction is no greater than the risk of using the reference product without such alternation or exchange. Biosimilars utilize the same mechanism of action for the proposed conditions of use, provided that these mechanisms are known to the reference product. One or more conditions of use specified, recommended or suggested in the label proposed for the biosimilar have been previously approved for the reference product. The route of administration, dosage form and / or potency of the biosimilar are the same as those of the reference product, and the biosimilar is manufactured, processed, packaged or stored in facilities that meet standards designed to ensure that the biosimilar is still safe, pure and potent. When compared to the reference product, the biosimilar may include slight modifications in the amino acid sequence, such as N- or C-terminal truncations that are not expected to change the performance of the biosimilar. The reference product may have been approved in at least one of the United States, Europe or Japan.

[0033] "CD38" refers to cluster of differentiation 38 protein, a glycoprotein expressed on immune cells, including plasma cells, natural killer cells, and B and T cell subsets.

[0034] "Cell culture medium" and "medium" refer to a solution containing components or nutrients that nourish growing mammalian cells. Typically, nutrients include essential and non-essential amino acids, vitamins, energy sources, lipids, and trace elements required for minimal growth and / or survival of the cells. Such solutions may also contain additional nutrients or supplemental components that enhance growth and / or survival above the minimum rate, including hormones and / or other growth factors, specific ions (such as sodium, chloride, calcium, magnesium, and phosphate), buffers, vitamins, nucleosides or nucleotides, trace elements (inorganic compounds usually present at very low final concentrations), inorganic compounds present at higher final concentrations (e.g., iron), amino acids, lipids, and / or glucose or other energy sources.

[0035] "Complementarity determining region (CDR)" is the region of an antibody that binds to an antigen. There are three CDRs in VH (HCDR1, HCDR2, HCDR3) and three CDRs in VL (LCDR1, LCDR2, LCDR3). CDRs can be defined using various depictions, such as Kabat (Wu et al., (1970) J Exp Med 132:211-50) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md., 1991), Chothia (Chothia et al., J Mol Biol 196:901-17, 1987), IMGT (Lefranc et al., Dev Comp Immunol 27:55-77, 2003) and AbM (Martin and Thornton, J Bmol Biol 263:800-15, 1996). The correspondence between various delineations and variable region numbers is described (see, e.g., Lefranc et al., Dev Comp Immunol 27:55-77, 2003; Honegger and Pluckthun, J Mol Biol 309:657-70, 2001; International Immunogenetics (IMGT) database; Web resources, http: / / www_imgt_org). Available programs (such as abYsis of UCL Business PLC) can be used to delineate CDRs. Unless otherwise expressly stated in the specification, as used herein, the terms "CDR", "HCDR1", "HCDR2", "HCDR3", "LCDR1", "LCDR2" and "LCDR3" include CDRs defined by any of the above methods (Kabat, Chothia, IMGT or AbM).

[0036] The transitional terms "comprising," "consisting essentially of," and "consisting of" are intended to suggest their recognized meanings in patent parlance; that is, (i) "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; (ii) "consisting of" excludes any element, step, or ingredient not specified in the claim; and (iii) "consisting essentially of" limits the scope of the claim to the specified materials or steps "and those that do not materially affect the basic and novel characteristics of the disclosure protected by the claims." Embodiments described with the phrase "comprising" (or its equivalent) are also provided, as are those embodiments described independently with "consisting of" and "consisting essentially of."

[0037] "Culture", "culture", "cultured" and "cell culture" refer to a population of cells suspended in a culture medium under conditions suitable for the survival and / or growth of the cell population. Cell culture includes fed-batch cell culture and perfusion cell culture.

[0038] "Drug substance" or "DS" means any substance or mixture of substances that is intended for use in the manufacture of a drug (medical) product and, when used in the manufacture of a drug, becomes the active ingredient of the drug product. Such substances are intended to provide pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or function of the body.

[0039] "Drug product" or "DP" refers to a finished dosage form, such as a tablet, capsule, or solution, containing an active pharmaceutical ingredient (eg, a drug substance), typically but not necessarily associated with inactive ingredients.

[0040] "Expression vector" refers to a vector that can be used in a biological system or a reconstituted biological system to direct the translation of a polypeptide encoded by a polynucleotide sequence present in the expression vector.

[0041] "GOF" refers to desialylated, galactose-free core fucosylated biantennary glycan.

[0042] "G0F oligosaccharide content" refers to the percentage of G0F oligosaccharides (G0F%) in glycoprotein oligosaccharides.

[0043] "G1F" refers to a desialylated monogalactose core fucosylated biantennary glycan.

[0044] "G1F oligosaccharide content" refers to the percentage of G1F oligosaccharides in glycoprotein oligosaccharides (G1F%).

[0045] "G2F" refers to a desialylated digalactosyl core fucosylated biantennary glycan.

[0046] "G2F oligosaccharide content" refers to the percentage of G2F oligosaccharides (G2F%) in glycoprotein oligosaccharides.

[0047] "GMP-compliant conditions" means manufacturing under the Good Manufacturing Practice (CGMP) regulations enforced by the U.S. Food and Drug Administration (FDA). CGMP provides a system to ensure the proper design, monitoring, and control of manufacturing processes and facilities. Compliance with CGMP regulations ensures the identity, potency, quality, and purity of drug products by requiring drug manufacturers to adequately control manufacturing operations. This includes establishing a strong quality management system; obtaining raw materials of appropriate quality; establishing robust operating procedures; detecting and investigating deviations in product quality; and maintaining reliable testing laboratories. This standardized control system at a pharmaceutical company, if fully put into practice, will help prevent contamination, mix-ups, deviations, failures, and errors. This ensures that the drug product meets its quality standards.

[0048] "Humanized antibody" refers to an antibody in which at least one CDR is derived from a non-human species and at least one framework is derived from a human immunoglobulin sequence. A humanized antibody may comprise substitutions in the framework so that the framework may not be an exact copy of an expressed human immunoglobulin or human immunoglobulin germline gene sequence.

[0049] "Human antibody" refers to an antibody that is optimized to have a minimal immune response when administered to a human subject. The variable region of a human antibody is derived from a human immunoglobulin sequence. If a human antibody comprises a constant region or a portion of a constant region, the constant region is also derived from a human immunoglobulin sequence. If the variable region of a human antibody is obtained by using a system of human germline immunoglobulins or rearranged immunoglobulin genes, the human antibody comprises a heavy chain variable region and a light chain variable region "derived from" a sequence of human origin. Such exemplary systems are human immunoglobulin gene libraries displayed on phages, and transgenic non-human animals, such as mice or rats carrying human immunoglobulin loci. Due to the differences between the systems for obtaining human antibodies and human immunoglobulin loci, the introduction of somatic mutations or the intentional introduction of substitutions into the framework or CDR or both, so "human antibodies" generally include amino acid differences compared to immunoglobulins expressed in humans. Typically, the amino acid sequence of a "human antibody" is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence encoded by a human germline immunoglobulin gene or a rearranged immunoglobulin gene. In some cases, a "human antibody" may comprise a consensus framework sequence obtained by human framework sequence analysis (e.g., as described in Knappik et al., J Mol Biol 296:57-86, 2000); or a synthetic HCDR3 bound to a human immunoglobulin gene library displayed on a phage (e.g., as described in Shi et al., J Mol Biol 397:385-96, 2010 and International Patent Publication WO 2009 / 085462). The definition of "human antibody" does not include antibodies in which at least one CDR is derived from a non-human species.

[0050] "Isolated" refers to a homogenous population of molecules (such as synthetic polynucleotides or proteins, such as antibodies) that have been substantially separated and / or purified from other components of a system (such as a recombinant cell) in which the molecules were produced, as well as proteins that have been subjected to at least one purification or separation step. "Isolated antibody" refers to an antibody that is substantially free of other cellular material and / or chemicals, and encompasses antibodies isolated to a higher degree of purity, such as 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% purity.

[0051] "Label" and "marking" are used interchangeably herein and refer to all labels and displays of written, printed, graphic information on, in, or associated with a container or package containing a drug (such as daratumumab) or that may otherwise be provided electronically or on the Internet. "Label" and "marking" include package inserts and prescribing information.

[0052] "Monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibody molecules, i.e., the individual antibodies comprising the population are identical except for possible well-known changes such as removal of the C-terminal lysine from the antibody heavy chain or post-translational modifications such as amino acid isomerization or deamidation, methionine oxidation, or asparagine or glutamine deamidation. A monoclonal antibody generally binds to one antigenic epitope. A monoclonal antibody may have heterogeneous glycosylation within the antibody population. A monoclonal antibody may be monospecific or multispecific, such as bispecific, monovalent, divalent or multivalent.

[0053] "Polynucleotide" refers to a synthetic molecule comprising a chain of nucleotides covalently linked to a phosphate sugar backbone or other equivalent covalent chemicals. cDNA is a typical example of a polynucleotide.

[0054] "ppb" or "parts per billion" refers to the amount of a metal in a solution or solid. When measured in a solution, ppb is equivalent to a concentration of μg / L of the metal in solution. When measured in a solid, ppb is equivalent to a concentration of μg / kg of the metal in solution.

[0055] "Recombinant" refers to polynucleotides, antibodies and other proteins prepared, expressed, formed or isolated by recombinant methods when fragments from different sources are joined to produce recombinant DNA, antibodies or proteins. "Recombinant antibodies" include all antibodies prepared, expressed, formed or isolated by recombinant methods, such as antibodies isolated from animals (e.g., mice) transgenic or transchromosomal for human immunoglobulin genes, or antibodies isolated from hybridomas prepared therefrom (described further below); antibodies isolated from host cells transformed to express antibodies; antibodies isolated from recombinant combinatorial antibody libraries; and antibodies prepared, expressed, formed or isolated by any other method involving splicing human immunoglobulin gene sequences with other DNA sequences, or antibodies such as bispecific antibodies generated in vitro using Fab arm exchange.

[0056] "Reference product" means the approved biological product to which the biosimilar product is compared. The reference product is approved based on, among other things, a complete complement of safety and efficacy data and has been approved in at least one of the United States, Europe, or Japan.

[0057] "Refractory" refers to a disease that does not respond to treatment. A refractory disease may be resistant to treatment before or at the start of treatment, or a refractory disease may become resistant during treatment.

[0058] "Relapse" refers to the reappearance of a disease or signs and symptoms of a disease after a period of improvement following previous treatment with a therapeutic agent.

[0059] "Specific binding" or "specifically binds" or "binding" means that the antibody binds to an antigen or an epitope within the antigen with a higher affinity than for other antigens. -8 M or less (e.g., about 1×10 -9 M or smaller, about 1×10 -10 M or smaller, about 1×10 -11 M or less or about 1×10 -12 M or less) D ) binds to an antigen or an epitope within an antigen, usually the K D The K of the antibody binding to nonspecific antigens (such as BSA, casein) D The dissociation constant is at most one hundredth of the antigen. Standard procedures can be used to measure the dissociation constant. However, an antibody that specifically binds to an antigen or an epitope within an antigen may have cross-reactivity to other related antigens, for example, to the same antigen from other species (homologous) such as humans or monkeys, e.g., cynomolgus (Macaca fascicularis) (cynomolgus, cyno), chimpanzee (Pantroglodytes) (chimpanzee, chimp) or marmoset (Callithrix jacchus) (common marmoset, marmoset).

[0060] "Subject" includes any human or non-human animal. "Non-human animals" include all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. The terms "subject" and "patient" are used interchangeably herein.

[0061] A "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the required dosage and time period. A therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic agent or combination of therapeutic agents to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic agent or combination of therapeutic agents include, for example, improving the health of the patient.

[0062] "Treat" or "treatment" refers to both therapeutic treatment and preventive or defensive measures, wherein the goal is to prevent or slow down (mitigate) undesirable physiological changes or disorders, such as complications caused by cancer. Beneficial or desired clinical results include alleviation of symptoms, reduction in the extent of the disease, a stable (i.e., non-worsening) state of the disease, a delay or slowing of disease progression, an improvement or alleviation of the disease state, and relief (whether partial or complete), whether detectable or undetectable. Individuals in need of treatment include individuals who already have a disorder or disorder as well as individuals who are susceptible to a disorder or disorder or individuals in whom a disorder or disorder is to be prevented.

[0063] "Vector" refers to a polynucleotide that can replicate within a biological system or can be moved between such systems. Vector polynucleotides typically contain elements such as an origin of replication, a polyadenylation signal, or a selectable marker, the function of which is to promote the replication or maintenance of these polynucleotides in a biological system. Examples of such biological systems may include cells, viruses, animals, plants, and biological systems recreated with biological components that can replicate the vector. The polynucleotide comprising the vector may be a DNA or RNA molecule or a hybrid molecule of these molecules.

[0064] Methods of the present disclosure

[0065] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding a heavy chain variable region (VH) of SEQ ID NO: 7 and a light chain variable region (VL) of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0066] preparing a culture medium comprising about 8.5 parts per billion (ppb) or less manganese (Mn); and

[0067] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0068] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0069] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0070] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0071] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0072] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0073] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0074] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0075] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0076] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0077] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 25%.

[0078] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%.

[0079] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 65% and about 74%.

[0080] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and 74%.

[0081] In some embodiments, preparing the culture medium includes measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting the one or more batches of raw material components that, when combined, contain about 8.5 ppb or less Mn.

[0082] In some embodiments, the culture medium is prepared to contain between about 4.0 ppb and about 8.5 ppb Mn.

[0083] In some embodiments, the culture medium is prepared to contain between about 4.0 ppb and about 6.5 ppb Mn.

[0084] In some embodiments, the culture medium is prepared to contain between about 5.0 ppb and about 6.5 ppb Mn.

[0085] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 27%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 65% and about 74%, and the culture medium is prepared to contain between about 4.0 ppb and about 8.5 ppb Mn.

[0086] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%, and the culture medium is prepared to contain between about 4.0 ppb and about 6.5 ppb Mn.

[0087] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%, and the culture medium is prepared to contain between about 5.0 ppb and about 6.5 ppb Mn.

[0088] In some embodiments, the anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 comprises the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8.

[0089] In some embodiments, the culture medium is a basal medium or a feed medium.

[0090] In some embodiments, culturing comprises fed-batch culturing or perfusion culturing.

[0091] In some embodiments, the host cell is a eukaryotic cell.

[0092] In some embodiments, the eukaryotic cell is a CHO cell, a PER.C6 cell, a NS0 cell, a Sp2 / 0 cell, or a BHK cell.

[0093] In some embodiments, the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell, or a CHO-DXB11 cell.

[0094] In some embodiments, the CHO cells lack glutamine synthetase (GS).

[0095] In some embodiments, the method is performed under GMP compliant conditions.

[0096] In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO:7 and the VL of SEQ ID NO:9.

[0097] In some embodiments, the anti-CD38 antibody comprises an IgG1 isotype.

[0098] In some embodiments, the anti-CD38 antibody comprises the heavy chain (HC) of SEQ ID NO:9 and the light chain (LC) of SEQ ID NO:10.

[0099] In some embodiments, the anti-CD38 antibody is a biosimilar.

[0100] In some embodiments, the anti-CD38 antibody is a biosimilar or (Daratumumab).

[0101] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0102] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0103] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0104] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0105] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0106] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0107] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0108] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0109] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0110] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0111] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0112] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0113] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0114] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0115] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0116] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0117] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0118] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0119] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0120] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0121] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0122] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0123] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0124] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0125] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0126] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0127] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0128] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0129] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0130] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0131] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0132] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0133] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0134] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0135] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0136] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0137] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 27%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0138] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0139] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0140] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0141] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0142] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0143] The present disclosure provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0144] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0145] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0146] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0147] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0148] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0149] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0150] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0151] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0152] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0153] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0154] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0155] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0156] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0157] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0158] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0159] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0160] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0161] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 25%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0162] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0163] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0164] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0165] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0166] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0167] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 25%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0168] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0169] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0170] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0171] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0172] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0173] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 21% and about 25%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0174] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0175] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0176] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0177] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0178] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0179] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 21% and about 25%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0180] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0181] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0182] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0183] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0184] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0185] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding a heavy chain (HC) of SEQ ID NO: 9 and a light chain (LC) of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0186] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0187] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0188] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0189] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0190] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0191] The present disclosure provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0192] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0193] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0194] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0195] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0196] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0197] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0198] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0199] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0200] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0201] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0202] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0203] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0204] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0205] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0206] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0207] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0208] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0209] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0210] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0211] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%.

[0212] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0213] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0214] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0215] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0216] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0217] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%.

[0218] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0219] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0220] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0221] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0222] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0223] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%.

[0224] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0225] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0226] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0227] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0228] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0229] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%.

[0230] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0231] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0232] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0233] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding a heavy chain variable region (VH) of SEQ ID NO: 7 and a light chain variable region (VL) of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0234] preparing a culture medium comprising about 8.5 parts per billion (ppb) or less manganese (Mn); and

[0235] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing Chinese hamster ovary (CHO) cells comprising polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0236] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0237] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0238] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium containing about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0239] The present disclosure provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0240] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0241] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0242] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0243] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0244] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0245] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0246] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0247] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0248] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0249] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0250] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0251] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0252] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0253] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0254] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0255] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0256] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0257] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0258] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0259] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0260] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0261] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0262] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium containing between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0263] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0264] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0265] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0266] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0267] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0268] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0269] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0270] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0271] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0272] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0273] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0274] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0275] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0276] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0277] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0278] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0279] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0280] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0281] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 27%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0282] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0283] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0284] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0285] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0286] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium containing about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0287] The present disclosure provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0288] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0289] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0290] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0291] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0292] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0293] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0294] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0295] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0296] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0297] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0298] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0299] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0300] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0301] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0302] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0303] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0304] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0305] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 25%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0306] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0307] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0308] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0309] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0310] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium containing between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0311] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 25%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0312] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0313] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0314] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0315] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0316] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0317] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 21% and about 25%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0318] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0319] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0320] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0321] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0322] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0323] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 21% and about 25%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0324] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0325] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0326] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, wherein the anti-CD38 antibody is an IgG1 isotype, the method comprising:

[0327] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0328] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0329] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding a heavy chain (HC) of SEQ ID NO: 9 and a light chain (LC) of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0330] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0331] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells containing polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium containing about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0332] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0333] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0334] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium containing about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0335] The present disclosure provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0336] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0337] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0338] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0339] preparing a culture medium comprising about 8.5 ppb or less Mn; and

[0340] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0341] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0342] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0343] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells containing polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium containing between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0344] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0345] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0346] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing a polynucleotide of HC of SEQ ID NO:9 and LC of SEQ ID NO:10 in a culture medium containing between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding HC of SEQ ID NO:9 and LC of SEQ ID NO:10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0347] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0348] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0349] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0350] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0351] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn; and

[0352] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing a polynucleotide comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium containing between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody containing the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0353] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0354] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0355] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells containing polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium containing between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 and having a G1F oligosaccharide content between about 15% and about 25%.

[0356] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0357] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0358] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium containing between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0359] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0360] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0361] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%.

[0362] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0363] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn; and

[0364] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0365] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0366] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0367] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells containing polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium containing between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 and having a G1F oligosaccharide content between about 21% and about 25%.

[0368] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0369] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0370] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells containing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium containing between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0371] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0372] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0373] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 and having a G1F oligosaccharide content between about 21% and about 25%.

[0374] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0375] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn; and

[0376] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 66% and about 74%.

[0377] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0378] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0379] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0380] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 25%.

[0381] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%.

[0382] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 65% and about 74%.

[0383] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and 74%.

[0384] In some embodiments, the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb Mn.

[0385] In some embodiments, the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb Mn.

[0386] In some embodiments, the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb Mn.

[0387] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 27%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 65% and about 74%, and the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb Mn.

[0388] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%, and the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb Mn.

[0389] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%, and the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb Mn.

[0390] In some embodiments, the culture medium is a basal medium or a feed medium.

[0391] In some embodiments, culturing comprises fed-batch culturing or perfusion culturing.

[0392] In some embodiments, the host cell is a eukaryotic cell.

[0393] In some embodiments, the eukaryotic cell is a CHO cell, a PER.C6 cell, a NS0 cell, a Sp2 / 0 cell, or a BHK cell.

[0394] In some embodiments, the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell, or a CHO-DXB11 cell.

[0395] In some embodiments, the CHO cells lack GS.

[0396] In some embodiments, the method is performed under GMP compliant conditions.

[0397] In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO:7 and the VL of SEQ ID NO:9.

[0398] In some embodiments, the anti-CD38 antibody comprises an IgG1 isotype.

[0399] In some embodiments, the anti-CD38 antibody comprises the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10.

[0400] In some embodiments, the anti-CD38 antibody is a biosimilar.

[0401] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0402] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0403] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0404] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0405] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0406] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0407] The present disclosure provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0408] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0409] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0410] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0411] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0412] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0413] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0414] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0415] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0416] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0417] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0418] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0419] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0420] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0421] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0422] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0423] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0424] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0425] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0426] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0427] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0428] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0429] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0430] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0431] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0432] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0433] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0434] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0435] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0436] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0437] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0438] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0439] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0440] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0441] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0442] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0443] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0444] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0445] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0446] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0447] Cultivating a host cell expressing a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions that produce an anti-CD38 antibody; and

[0448] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0449] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0450] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0451] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0452] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0453] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0454] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and 74%.

[0455] The present disclosure provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0456] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0457] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0458] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0459] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0460] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0461] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0462] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0463] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0464] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0465] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0466] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0467] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0468] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0469] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0470] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0471] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0472] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0473] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0474] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0475] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%.

[0476] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0477] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0478] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0479] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0480] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0481] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%.

[0482] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0483] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0484] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0485] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0486] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0487] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%.

[0488] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0489] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0490] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0491] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0492] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0493] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%.

[0494] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0495] Cultivating a host cell expressing a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where an anti-CD38 antibody is produced; and

[0496] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0497] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0498] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0499] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0500] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0501] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0502] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0503] The present disclosure provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0504] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0505] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0506] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0507] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0508] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0509] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0510] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0511] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0512] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0513] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0514] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0515] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0516] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0517] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27%.

[0518] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0519] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0520] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0521] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0522] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0523] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0524] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0525] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0526] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0527] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0528] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0529] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25%.

[0530] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0531] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0532] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0533] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0534] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0535] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0536] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0537] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0538] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0539] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0540] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0541] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25%.

[0542] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0543] Culturing CHO cells expressing polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 under conditions that produce anti-CD38 antibodies; and

[0544] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0545] The present disclosure provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0546] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0547] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0548] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0549] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0550] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and 74%.

[0551] The present disclosure provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0552] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0553] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0554] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0555] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0556] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0557] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0558] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0559] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0560] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0561] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0562] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0563] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%, the method comprising:

[0564] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0565] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27%.

[0566] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0567] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0568] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%.

[0569] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0570] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0571] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%.

[0572] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0573] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0574] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0575] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%, the method comprising:

[0576] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0577] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25%.

[0578] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0579] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0580] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0581] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0582] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0583] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%.

[0584] The present disclosure also provides a method of producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0585] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0586] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0587] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%, the method comprising:

[0588] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0589] The G1F oligosaccharide content of the anti-CD38 antibody is controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25%.

[0590] The present disclosure also provides a method of producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0591] Culturing CHO cells expressing polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 under conditions where anti-CD38 antibodies are produced; and

[0592] The G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody are controlled by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody comprising the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%.

[0593] The present disclosure also provides a method for producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%, the method comprising: culturing a host cell comprising a polynucleotide encoding an anti-CD38 antibody in a culture medium measured to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0594] The present disclosure also provides a method for producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%, the method comprising: culturing a host cell comprising a polynucleotide encoding an anti-CD38 antibody in a culture medium controlled to contain about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0595] The present disclosure also provides a method for producing an anti-CD38 antibody having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising: culturing a host cell comprising a polynucleotide encoding the anti-CD38 antibody in a culture medium comprising 8.5 ppb or less Mn, and controlling the G1F oligosaccharide content by monitoring the concentration of Mn in the culture medium during biosynthesis of the antibody and adjusting the concentration of Mn in the culture medium during biosynthesis of the antibody, thereby producing the antibody.

[0596] The present disclosure also provides a method of producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and 27%, the method comprising: culturing a host cell transfected with a polynucleotide encoding the anti-CD38 antibody in a culture medium comprising about 8.0 ppb or less Mn, thereby producing the antibody.

[0597] The present disclosure also provides a method for producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and 27%, the method comprising: preparing a culture medium comprising about 8.5 ppb or less Mn; and culturing a host cell comprising a polynucleotide encoding the anti-CD38 antibody in the culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and 27%.

[0598] The present disclosure also provides a method for producing an antibody having a G1F oligosaccharide content between about 15% and 27%, the method comprising: preparing a culture medium comprising about 8.0 ppb or less Mn; and culturing a host cell transfected with a polynucleotide encoding the antibody in the culture medium comprising about 8.0 ppb or less Mn, thereby producing the antibody.

[0599] The present disclosure provides a method for controlling the G1F oligosaccharide content of an anti-CD38 antibody during biosynthesis of the antibody in a culture medium to have a G1F oligosaccharide content between about 15% and 27%, wherein the method comprises: monitoring the Mn level in the culture medium during the biosynthesis of the antibody; and adjusting the Mn level in the culture medium during the biosynthesis of the antibody or an antigen-binding fragment thereof.

[0600] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 26%.

[0601] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 25%.

[0602] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 16% and about 26%.

[0603] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 17% and about 26%.

[0604] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 18% and about 26%.

[0605] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 19% and about 26%.

[0606] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 20% and about 26%.

[0607] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%.

[0608] In some embodiments, the antibody has a GOF content between about 68% and 74%.

[0609] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 65% and 74%.

[0610] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 66% and 74%.

[0611] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 67% and about 74%.

[0612] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%.

[0613] In some embodiments, preparing the culture medium includes measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting to prepare the culture medium those one or more batches of raw material components that, when combined, contain about 8.5 ppb or less Mn.

[0614] In some embodiments, preparing the culture medium includes measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting to prepare the culture medium those one or more batches of raw material components that, when combined, contain about 8.0 ppb or less Mn.

[0615] In some embodiments, preparing the culture medium includes measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting to prepare the culture medium those one or more batches of raw material components that, when combined, contain about 6.5 ppb or less Mn.

[0616] In some embodiments, preparing the culture medium includes measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting those one or more batches of raw material components that, when combined, contain between about 4.0 ppb to about 8.5 ppb Mn to prepare the culture medium.

[0617] In some embodiments, preparing the culture medium includes measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting those one or more batches of raw material components that, when combined, contain between about 4.0 ppb to about 6.5 ppb Mn to prepare the culture medium.

[0618] In some embodiments, the culture medium is prepared to contain about 8.0 ppb, about 7.5 ppb or less, about 7.0 ppb or less, about 6.5 ppb or less, about 6.0 ppb or less, about 5.5 ppb or less, or about 5.5 ppb or less Mn.

[0619] In some embodiments, the culture medium is prepared to contain about 8.5 ppb or less Mn.

[0620] In some embodiments, the culture medium is prepared to contain about 8.0 ppb or less Mn.

[0621] In some embodiments, the culture medium is prepared to contain about 7.5 ppb or less Mn.

[0622] In some embodiments, the culture medium is prepared to contain about 7.0 ppb or less Mn.

[0623] In some embodiments, the culture medium is prepared to contain about 6.5 ppb or less Mn.

[0624] In some embodiments, the culture medium is prepared to contain about 6.0 ppb or less Mn.

[0625] In some embodiments, the culture medium is prepared to contain about 5.5 ppb or less Mn.

[0626] In some embodiments, the culture medium is prepared to contain about 5.0 ppb or less Mn.

[0627] In some embodiments, the culture medium is prepared to contain between about 2 ppb and about 8.0 ppb Mn.

[0628] In some embodiments, the culture medium is prepared to contain between about 2 ppb and about 8.5 ppb Mn.

[0629] In some embodiments, the culture medium is prepared to contain between about 2 ppb and about 6.5 ppb Mn.

[0630] In some embodiments, the culture medium is prepared to contain between about 5.0 ppb and about 8.0 ppb Mn.

[0631] In some embodiments, the culture medium is prepared to contain between about 5.0 ppb and about 7.5 ppb Mn.

[0632] In some embodiments, the culture medium is prepared to contain between about 5.0 ppb and about 7.0 ppb Mn.

[0633] In some embodiments, the culture medium is prepared to contain between about 5.0 ppb and about 6.5 ppb Mn.

[0634] In some embodiments, the culture medium is prepared to contain between about 4.0 ppb and about 6.5 ppb Mn.

[0635] In some embodiments, the culture medium is prepared to contain between about 4.0 ppb and about 8.5 ppb Mn.

[0636] In some embodiments, the culture medium comprises about 8.5 ppb, 8.0 ppb, about 7.5 ppb or less, about 7.0 ppb or less, about 6.5 ppb or less, about 6.0 ppb or less, about 5.5 ppb or less, or about 5.0 ppb or less Mn.

[0637] In some embodiments, the culture medium comprises about 8.5 ppb or less Mn.

[0638] In some embodiments, the culture medium comprises about 8.0 ppb or less Mn.

[0639] In some embodiments, the culture medium comprises about 7.5 ppb or less Mn.

[0640] In some embodiments, the culture medium comprises about 7.0 ppb or less Mn.

[0641] In some embodiments, the culture medium comprises about 6.5 ppb or less Mn.

[0642] In some embodiments, the culture medium comprises about 6.0 ppb or less Mn.

[0643] In some embodiments, the culture medium comprises about 5.5 ppb or less Mn.

[0644] In some embodiments, the culture medium comprises about 5.0 ppb or less Mn.

[0645] In some embodiments, the culture medium comprises between about 2 ppb and about 8.0 ppb Mn.

[0646] In some embodiments, the culture medium comprises between about 2 ppb and about 6.5 ppb Mn.

[0647] In some embodiments, the culture medium comprises between about 5.0 ppb and about 8.0 ppb Mn.

[0648] In some embodiments, the culture medium comprises between about 5.0 ppb and about 7.5 ppb Mn.

[0649] In some embodiments, the culture medium comprises between about 5.0 ppb and about 7.0 ppb Mn.

[0650] In some embodiments, the culture medium comprises between about 5.0 ppb and about 6.5 ppb Mn.

[0651] In some embodiments, the culture medium comprises between about 4.0 ppb and about 6.5 ppb Mn.

[0652] In some embodiments, the culture medium comprises between about 4.0 ppb and about 8.5 ppb Mn.

[0653] In some embodiments, the culture medium is controlled to contain about 8.0 ppb, about 7.5 ppb or less, about 7.0 ppb or less, about 6.5 ppb or less, about 6.0 ppb or less, about 5.5 ppb or less, or about 5.5 ppb or less Mn.

[0654] In some embodiments, the culture medium is controlled to contain about 8.5 ppb or less Mn.

[0655] In some embodiments, the culture medium is controlled to contain about 8.0 ppb or less Mn.

[0656] In some embodiments, the culture medium is controlled to contain about 7.5 ppb or less Mn.

[0657] In some embodiments, the culture medium is controlled to contain about 7.0 ppb or less Mn.

[0658] In some embodiments, the culture medium is controlled to contain about 6.5 ppb or less Mn.

[0659] In some embodiments, the culture medium is controlled to contain about 6.0 ppb or less Mn.

[0660] In some embodiments, the culture medium is controlled to contain about 5.5 ppb or less Mn.

[0661] In some embodiments, the culture medium is controlled to contain about 5.0 ppb or less Mn.

[0662] In some embodiments, the culture medium is controlled to contain between about 2 ppb and about 8.0 ppb Mn.

[0663] In some embodiments, the culture medium is controlled to contain between about 2 ppb and about 6.5 ppb Mn.

[0664] In some embodiments, the culture medium is controlled to contain between about 5.0 ppb and about 8.0 ppb Mn.

[0665] In some embodiments, the culture medium is controlled to contain between about 5.0 ppb and about 7.5 ppb Mn.

[0666] In some embodiments, the culture medium is controlled to contain between about 5.0 ppb and about 7.0 ppb Mn.

[0667] In some embodiments, the culture medium is controlled to contain between about 5.0 ppb and about 6.5 ppb Mn.

[0668] In some embodiments, the culture medium is controlled to contain between about 4.0 ppb and about 6.5 ppb Mn.

[0669] In some embodiments, the culture medium is controlled to contain between about 4.0 ppb and about 8.5 ppb Mn.

[0670] In some embodiments, the culture is a fed-batch culture. In some embodiments, the culture is a perfusion culture.

[0671] In some embodiments, the culture medium is a basal medium or a feed medium. In some embodiments, the culture medium is a basal medium. In some embodiments, the culture medium is a feed medium.

[0672] In some embodiments, the method is performed under GMP compliant conditions.

[0673] Any one or more culture media or combinations thereof can be used in the methods of the present disclosure. Culture media are well known and include Eagle's MEME (minimum essential medium), Ham's F12, F-12K medium, Dulbecco's medium, Dulbecco's Modified Eagle medium, DMEM / Ham's F12 1:1, Trowell's T8, A2 medium, Waymouth medium, Williams E medium, RPMI 1640, MCDB 104 / 110 medium, Ventrex HL-1 medium, albumin-globulin medium, RPMI-1640 medium, RPMI-1641 medium, Iscove's Modified Dulbecco's medium, McCoy's 5A medium, Leibovitz's L-15 medium, and serum-free medium such as EX-CELL TM300 series, protamine-zinc-insulin medium (U.S. Patent 4,072,565), biotin-folic acid medium, transferrin-fatty acid medium (U.S. Patent 4,560,655), transferrin-EGF medium (U.S. Patent 4,615,977; U.S. Patent 4,786,599), and other media arrays (U.S. Patent 6,048,728; U.S. Patent 7,294,484; U.S. Patent 5,122,469; U.S. Patent 5,976,833; U.S. Patent 6,180,401; U.S. Patent 5,856,179; U.S. Patent 5,705,364; U.S. Patent 7,666,416; U.S. Patent 6,528,286; U.S. Patent 6,924,124; U.S. Patent 7,429,491) and other chemically defined media. Media compositions are often available from suppliers.

[0674] "Chemically defined medium" refers to a synthetic growth medium in which the identities and concentrations of all components are known. Chemically defined media do not contain bacteria, yeast, animal or plant extracts, animal serum or plasma, but they may or may not include individual plant or animal derived components (e.g., proteins, polypeptides, etc.). Chemically defined media may contain inorganic salts required to support growth, such as phosphates, sulfates, etc. The carbon source is defined and is typically a sugar such as glucose, lactose, galactose, etc., or other compounds such as glycerol, lactate, acetate, etc. Although some chemically defined media also use phosphate as a buffer, other buffers such as citrate, triethanolamine, etc. may also be used. Examples of commercially available chemically defined media include ThermoFisher's CD Hybridoma Medium and CD Hybridoma AGT TM Medium, various Dulbecco's Modified Eagle's (DME) media (Sigma-Aldrich Co; SAFC Biosciences, Inc), Ham's nutrient mixture (Sigma-Aldrich Co; SAFC Biosciences, Inc), combinations thereof, and the like. Methods for preparing chemically defined media are known in the art, such as those described in U.S. Pat. No. 6,171,825 and U.S. Pat. No. 6,936,441, International Patent Publication WO2007 / 077217, and U.S. Pat. No. 2008 / 0009040 and U.S. Pat. No. 2007 / 0212770. The exemplary culture media described herein can be used as a basal medium or a feed medium. Chemically defined media feeds designed to provide cell culture nutrients for the fed-batch process for culturing CHO cells include those available from Irivne Scientific, such as CHO feed powder or liquid medium.

[0675] Exemplary components of culture media include essential and non-essential amino acids, vitamins, energy sources, lipids, and trace elements.

[0676] The method of the present disclosure can be used together with any cell culture method suitable for the desired process (e.g., the production of recombinant antibodies). Cells can be grown in batches or fed-batch cultures, wherein the culture is terminated after the antibody is fully expressed, and the expressed antibody is harvested afterwards. Alternatively, cells can be grown in batches again in fed-batch cultures, wherein the culture is not terminated, but new nutrients and other components are periodically or continuously added to the culture, and the expressed antibody is periodically or continuously harvested during the culture. Other suitable methods (e.g., rotary tube cultures) are known in the art and can also be used.

[0677] In some embodiments, the culture is a fed-batch culture. In some embodiments, the culture is a batch re-fed culture. "Fed-batch culture" refers to a cell culture method that provides additional components to the culture at one or more times after the culture process begins. Such components provided generally include nutritional components of cells that have been exhausted during the culture process. Fed-batch culture is usually stopped at a certain time point, and cells and / or components in the culture medium are harvested and optionally purified. In some embodiments, the fed-batch culture includes a basal medium supplemented with a feed medium. The cell can grow in any convenient volume. For example, the cell can grow in a small-scale reaction vessel in a volume range of several milliliters to several liters. Alternatively, the cell can grow in a large-scale commercial bioreactor in a volume range of about at least 1 liter to 10, 50, 100, 250, 500, 1000, 2500, 5000, 8000, 10,000, 12,000, 15000, 20000 or 25000 liters or more or any volume therebetween.

[0678] A culture medium comprising about 8.5ppb or less manganese can be prepared in the following manner: the manganese concentration in each batch of each raw material component of the culture medium is analyzed and the batches of raw material components with a manganese concentration of about 8.5ppb or less are selected to prepare the culture medium, or the total manganese concentration in the selected components when combined together is about 8.5ppb or less. A culture medium comprising about 8.0ppb or less manganese can be prepared in the following manner: the manganese concentration in each batch of each raw material component of the culture medium is analyzed and the batches of raw material components with a manganese concentration of about 8.0ppb or less are selected to prepare the culture medium, or the total manganese concentration in the selected components when combined together is about 8.0ppb or less. A culture medium comprising about 6.5ppb or less manganese can be prepared in the following manner: the manganese concentration in each batch of each raw material component of the culture medium is analyzed and the batches of raw material components with a manganese concentration of about 6.5ppb or less are selected to prepare the culture medium, or the total manganese concentration in the selected components when combined together is about 6.5ppb or less. Manganese concentration can be measured in raw material components or culture medium using the methods described herein.

[0679] In some embodiments, the host cell is a eukaryotic cell. Exemplary eukaryotic cells can be mammals, insects, birds or other animal sources. Mammalian eukaryotic cells include immortalized cell lines, such as hybridomas or myeloma cell lines, such as SP2 / 0 (American Type Culture Collection (ATCC), Manassas, VA, CRL-1581), NS0 (European Cell Culture Collection (ECACC), Salisbury, Wiltshire, UK, ECACC No.85110503), FO (ATCC CRL-1646) and Ag653 (ATCC CRL-1580) mouse cell lines. An exemplary human myeloma cell line is U266 (ATTCCRL-TIB-196). Other useful cell lines include those derived from Chinese hamster ovary (CHO) cells, such as HD-BIOP3 GS Null CHO K1 (Horizon Discovery Limited, Cambridge, UK), CHO-K1SV (Lonza Biologics, Walkersville, MD), CHO-K1 (ATCC CRL-61), DG44, CHO-S, or CHO-DXB11.

[0680] In some embodiments, the host cell is a CHO cell, a PER.C6 cell, a NSO cell, a Sp2 / 0 cell, or a BHK cell.

[0681] In some embodiments, the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell, or a CHO-DXB11 cell.

[0682] In some embodiments, the CHO cells lack glutamine synthetase (GS). Methods for using GS as a selectable marker for mammalian cells are known.

[0683] In some embodiments, the methods of the present disclosure are performed under GMP compliant conditions.

[0684] In some embodiments, the anti-CD38 antibody comprises a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively.

[0685] In some embodiments, the anti-CD38 antibody is expressed by polynucleotides encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively.

[0686] In some embodiments, the anti-CD38 antibody comprises a heavy chain variable region (VH) of SEQ ID NO:7 and a light chain variable region (VL) of SEQ ID NO:8.

[0687] In some embodiments, the anti-CD38 antibody is expressed by a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8.

[0688] In some embodiments, the anti-CD38 antibody is of the IgG1 isotype. In some embodiments, the anti-CD38 antibody is of the IgG2 isotype. In some embodiments, the anti-CD38 antibody is of the IgG4 isotype.

[0689] In some embodiments, the anti-CD38 antibody comprises the heavy chain (HC) of SEQ ID NO:9 and the light chain (LC) of SEQ ID NO:10.

[0690] In some embodiments, the anti-CD38 antibody is expressed by a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10.

[0691] In some embodiments, the anti-CD38 antibody is (Daratumumab).

[0692] In some embodiments, the anti-CD38 antibody is (daratumumab) biosimilars.

[0693] In some embodiments, the anti-CD38 antibody is MOR-202 (MOR-03087) comprising the VH and VL of SEQ ID NOs: 11 and 12, respectively, as described in US Patent No. 8,088, 896. The VH and VL of MOR-202 can be expressed as IgG1 / κ.

[0694] In some embodiments, the anti-CD38 antibody is isatuximab comprising the VH and VL of SEQ ID NOs: 13 and 14, respectively, as described in U.S. Patent No. 8,153,765. The VH and VL of isatuximab can be expressed as IgG1 / κ.

[0695] SEQ ID NO:1

[0696] SFAMS

[0697] SEQ ID NO:2

[0698] AISGSGGGTYYADSVKG

[0699] SEQ ID NO:3

[0700] DKILWFGEPVFDY

[0701] SEQ ID NO:4

[0702] RASQSVSSYLA

[0703] SEQ ID NO:5

[0704] DASNRAT

[0705] SEQ ID NO:6

[0706] QQRSNWPPTF

[0707] SEQ ID NO:7

[0708] EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSA

[0709] ISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDK

[0710] ILWFGEPVFDYWGQGTLVTVSS

[0711] SEQ ID NO:8

[0712] EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK

[0713] SEQ ID NO:9

[0714] EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0715] SEQ ID NO:10

[0716] EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0717] SEQ ID NO:11

[0718] QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS

[0719] SEQ ID NO:12

[0720] DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ

[0721] SEQ ID NO:13

[0722] QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGT

[0723] IYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGD

[0724] YYGSNSLDYWGQGTSVTVSS

[0725] SEQ ID NO:14

[0726] DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK

[0727] Methods for measuring the oligosaccharide composition of antibodies

[0728] Agilent 1100 / 1200 series HPLC systems and Chemstation / Chemstore software can be used to determine the oligosaccharide composition of the antibody using HPLC method. In order to quantify the relative amount of polysaccharide, first use N-glycanase (PNGase F) to crack the oligosaccharide connected from the test article of reduction and denaturation. The released polysaccharide is labeled using o-aminobenzoic acid, purified by filtering using 0.45 μm nylon filter, and analyzed by HPLC with fluorescence detection. HPLC chromatogram serves as a distribution diagram that can be used to identify and quantify the relative amount of the oligosaccharide connected by N present in the sample. Polysaccharide is identified by co-elution and retention time with oligosaccharide standards.

[0729] The amount of each polysaccharide is quantitatively expressed as the percentage (peak area %) of the total polysaccharide peak area by peak area integration. The results of G0F, G1F, G2F, total neutral substances and total charged polysaccharides can be reported. Other neutral polysaccharides can also be analyzed, and these neutral polysaccharides are the sum of all integrated peaks eluted in the system between 17 and 35 minutes except the peak corresponding to G0F, G1F and G2F. Total neutral polysaccharides are the sum of G0F, G1F, G2F and other neutral substances. Total charged polysaccharides are the sum of all monosialylated polysaccharide peaks eluted in the system between 42 and 55 minutes and all disialylated polysaccharide peaks eluted between 78 and 90 minutes.

[0730] The mixture of oligosaccharide standards (GOF, G2F, G2F+N-acetylneuraminic acid (NANA) and G2F+2NANA) was analyzed in parallel as a positive control for the labeling reaction, as a standard for peak identification, and as a measure of system suitability. The oligosaccharide G0F (catalog number GKC-004301), G2F (catalog number GKC-024301), SA1F (catalog number GKC-124301) and SA2F (catalog number GKC-224301) or equivalents purchased from the reconstruction of Prozyme were used as reference standards. For system suitability purposes, method blank negative controls and pre-labeled G0F standards were also run.

[0731] Method for measuring manganese concentration in culture medium and dry powder

[0732] Manganese concentrations in materials and solutions can be measured using known methods and those described herein. Inductively coupled plasma mass spectrometry (ICP-MS) can be used to quantify trace metal concentrations in test samples in parts per billion (ppb, μg / liter). The carbon-rich source can be digested into carbon dioxide and water using an acid digestion procedure before using a 350X ICP-MS (PerkinElmer). Wet chemical digestion can utilize different acids and oxidants, such as nitric acid (HNO3), hydrogen peroxide (H2O2), and hydrochloric acid (HCl).

[0733] Methods of producing antibodies

[0734] The method of producing antibody on a large scale is known. Antibodies can be produced, for example, in CHO cells cultivated using known methods. As the first step in the purification process, solids can be removed by centrifugation or filtration to separate and / or purify antibodies from the culture medium. Antibodies can be further purified by standard methods or by any other available techniques for purifying antibodies, including chromatography (e.g., ion exchange chromatography, affinity chromatography, size exclusion chromatography, and hydroxyapatite chromatography), gel filtration, centrifugation or differential solubility, ethanol precipitation. Protease inhibitors such as phenylmethylsulfonyl fluoride (PMSF), leupeptin, pepstatin or aprotinin can be added at any or all stages to reduce or eliminate the degradation of antibodies during the purification process. Those of ordinary skill in the art will appreciate that definite purification techniques will vary according to the characteristics of the polypeptide or protein to be purified, the characteristics of the cells expressing the polypeptide or protein, and the composition of the culture medium in which the cells grow therein.

[0735] Methods of producing drug products

[0736] The methods disclosed herein also include methods of producing a pharmaceutical product. For example, the present disclosure provides a method of producing a pharmaceutical product, the method comprising performing the steps of the method of producing an antibody as disclosed above.

[0737] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0738] preparing a culture medium comprising about 8.5 ppb or less Mn;

[0739] controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing a host cell comprising a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in the culture medium prepared in step a), thereby producing an anti-CD38 antibody having a G1F oligosaccharide content of between about 15% and about 27%; and

[0740] The anti-CD38 antibody is formulated as a drug product.

[0741] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 25%.

[0742] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%.

[0743] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 65% and about 74%.

[0744] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and 74%.

[0745] In some embodiments, preparing the culture medium includes measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting the one or more batches of raw material components that, when combined, contain about 8.5 ppb or less Mn.

[0746] In some embodiments, the culture medium is prepared to contain between about 4.0 ppb and about 8.5 ppb Mn.

[0747] In some embodiments, the culture medium is prepared to contain between about 4.0 ppb and about 6.5 ppb Mn.

[0748] In some embodiments, the culture medium is prepared to contain between about 5.0 ppb and about 6.5 ppb Mn.

[0749] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 27%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 65% and about 74%, and the culture medium is prepared to contain between about 4.0 ppb and about 8.5 ppb Mn.

[0750] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 15% and about 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%, and the culture medium is prepared to contain between about 4.0 ppb and about 6.5 ppb Mn.

[0751] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%, and the culture medium is prepared to contain between about 5.0 ppb and about 6.5 ppb Mn.

[0752] In some embodiments, the culture medium is a basal medium or a feed medium.

[0753] In some embodiments, culturing comprises fed-batch culturing or perfusion culturing.

[0754] In some embodiments, the host cell is a eukaryotic cell.

[0755] In some embodiments, the eukaryotic cell is a CHO cell, a PER.C6 cell, a NS0 cell, a Sp2 / 0 cell, or a BHK cell.

[0756] In some embodiments, the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell, or a CHO-DXB11 cell.

[0757] In some embodiments, the CHO cells lack glutamine synthetase (GS).

[0758] In some embodiments, the method is performed under GMP compliant conditions.

[0759] In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO:7 and the VL of SEQ ID NO:9.

[0760] In some embodiments, the anti-CD38 antibody comprises an IgG1 isotype.

[0761] In some embodiments, the anti-CD38 antibody comprises the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10.

[0762] In some embodiments, the anti-CD38 antibody is a biosimilar.

[0763] In some embodiments, a formulated drug product comprises about 120 mg / mL of an anti-CD38 antibody in about 2,000 U / ml recombinant human hyaluronidase (rHuPH20), about 5 mM to about 15 mM histidine, about 100 mM to about 300 mM sorbitol, about 0.01% w / v to about 0.04% w / v PS-20, and about 1 mg / mL to about 2 mg / mL methionine, at a pH of about 5.6.

[0764] In some embodiments, formulating the drug product comprises formulating 20 mg / ml of the anti-CD38 antibody in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); the pH is about 5.5.

[0765] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0766] preparing a culture medium comprising about 8.5 ppb or less Mn;

[0767] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%; and

[0768] The anti-CD38 antibody is formulated as a drug product.

[0769] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0770] preparing a culture medium comprising about 8.5 ppb or less Mn;

[0771] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing an anti-CD38 antibody expressed by polynucleotides encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%; and

[0772] The anti-CD38 antibody is formulated as a drug product.

[0773] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0774] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0775] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%; and

[0776] The anti-CD38 antibody is formulated as a drug product.

[0777] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0778] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0779] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%; and

[0780] The anti-CD38 antibody is formulated as a drug product.

[0781] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 25%, the method comprising:

[0782] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0783] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 25%; and

[0784] The anti-CD38 antibody is formulated as a drug product.

[0785] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0786] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0787] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0788] The anti-CD38 antibody is formulated as a drug product.

[0789] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 21% and about 25%, the method comprising:

[0790] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0791] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 21% and about 25%; and

[0792] The anti-CD38 antibody is formulated as a drug product.

[0793] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0794] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0795] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0796] The anti-CD38 antibody is formulated as a drug product.

[0797] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0798] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0799] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 27%; and

[0800] The anti-CD38 antibody is formulated as a drug product.

[0801] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0802] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0803] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%; and formulating the anti-CD38 antibody as a pharmaceutical product.

[0804] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 25%, the method comprising:

[0805] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0806] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 25%; and

[0807] The anti-CD38 antibody is formulated as a drug product.

[0808] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0809] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0810] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and formulating the anti-CD38 antibody as a pharmaceutical product.

[0811] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 21% and about 25%, the method comprising:

[0812] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0813] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 21% and about 25%; and

[0814] The anti-CD38 antibody is formulated as a drug product.

[0815] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0816] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0817] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0818] The anti-CD38 antibody is formulated as a drug product.

[0819] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises formulating about 20 mg / ml of the anti-CD38 antibody in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); the pH is about 5.5.

[0820] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises using recombinant human hyaluronidase (rHuPH20) in an amount of about 30,000 U to about 45,000 U to formulate about 20 mg / mL to about 180 mg / mL of the anti-CD38 antibody.

[0821] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises using about 30,000 U of rHuPH20 to formulate about 120 mg / mL of the anti-CD38 antibody.

[0822] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises formulating about 120 mg / mL of the anti-CD38 antibody using about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, with a pH of about 5.6.

[0823] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises formulating about 120 mg / mL of the anti-CD38 antibody using about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, with a pH of about 5.5.

[0824] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises using recombinant human hyaluronidase (rHuPH20) in an amount of about 30,000 U to about 45,000 U, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, PS-20 at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL to formulate about 20 mg / mL to about 180 mg / mL of the anti-CD38 antibody, with a pH of about 5.6.

[0825] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises using recombinant human hyaluronidase (rHuPH20) in an amount of about 30,000 U to about 45,000 U, histidine in a concentration of about 5 mM to about 15 mM, sorbitol in a concentration of about 100 mM to about 300 mM, PS-20 in a concentration of about 0.01% w / v to about 0.04% w / v, and methionine in a concentration of about 1 mg / mL to about 2 mg / mL to formulate about 20 mg / mL to about 180 mg / mL of the anti-CD38 antibody, with a pH of about 5.5.

[0826] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises using about 2,000 U / ml of rHuPH20, 10 mM histidine, about 300 mM sorbitol, about 1 mg / mL methionine, about 0.04% polysorbate 20, and about 2000 U / ml rHuPH20 to formulate about 120 mg / mL of the anti-CD38 antibody at a pH of 5.6.

[0827] In some embodiments, the step of formulating the anti-CD38 antibody as a drug product comprises using about 2,000 U / ml of rHuPH20, 10 mM histidine, about 300 mM sorbitol, about 1 mg / mL methionine, about 0.04% polysorbate 20, and about 2000 U / ml rHuPH20 to formulate about 120 mg / mL of the anti-CD38 antibody at a pH of 5.5.

[0828] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0829] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0830] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%; and

[0831] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0832] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0833] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0834] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%; and

[0835] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0836] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 25%, the method comprising:

[0837] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0838] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 25%; and

[0839] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0840] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0841] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0842] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0843] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0844] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 21% and about 25%, the method comprising:

[0845] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0846] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 21% and about 25%; and

[0847] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0848] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0849] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0850] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0851] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0852] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0853] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0854] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 27%; and

[0855] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0856] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0857] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0858] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%; and

[0859] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0860] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 25%, the method comprising:

[0861] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0862] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 25%; and

[0863] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0864] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0865] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0866] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0867] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0868] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 21% and about 25%, the method comprising:

[0869] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0870] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 21% and about 25%; and

[0871] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0872] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0873] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0874] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0875] About 20 mg / ml of anti-CD38 antibody was formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH was about 5.5.

[0876] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0877] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0878] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 27%; and

[0879] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0880] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0881] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0882] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%; and

[0883] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0884] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 15% and about 25%, the method comprising:

[0885] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0886] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 15% and about 25%; and

[0887] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0888] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0889] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0890] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0891] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0892] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content of between about 21% and about 25%, the method comprising:

[0893] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0894] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8 and having a G1F oligosaccharide content of between about 21% and about 25%; and

[0895] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0896] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0897] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0898] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0899] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0900] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 27%, the method comprising:

[0901] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0902] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 27%; and

[0903] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0904] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%, the method comprising:

[0905] preparing a culture medium comprising between about 4.0 ppb and about 8.5 ppb Mn;

[0906] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 8.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 27% and a G0F oligosaccharide content between about 65% and about 74%; and

[0907] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0908] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 25%, the method comprising:

[0909] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0910] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 15% and about 25%; and

[0911] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0912] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0913] preparing a culture medium comprising between about 4.0 ppb and about 6.5 ppb Mn;

[0914] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 4.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 15% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0915] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0916] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 21% and about 25%, the method comprising:

[0917] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0918] Controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content of between about 21% and about 25%; and

[0919] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0920] The present disclosure also provides a method of producing a drug product comprising an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%, the method comprising:

[0921] preparing a culture medium comprising between about 5.0 ppb and about 6.5 ppb Mn;

[0922] Controlling the G1F oligosaccharide content and the G0F oligosaccharide content of the anti-CD38 antibody by culturing CHO cells comprising a polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 in a culture medium comprising between about 5.0 ppb and about 6.5 ppb of Mn, thereby producing an anti-CD38 antibody expressed by the polynucleotide encoding the HC of SEQ ID NO: 9 and the LC of SEQ ID NO: 10 and having a G1F oligosaccharide content between about 21% and about 25% and a G0F oligosaccharide content between about 68% and about 74%; and

[0923] About 120 mg / mL of anti-CD38 antibody is formulated with about 2,000 U / ml of rHuPH20, histidine at a concentration of about 5 mM to about 15 mM, sorbitol at a concentration of about 100 mM to about 300 mM, polysorbate 20 (PS-20) at a concentration of about 0.01% w / v to about 0.04% w / v, and methionine at a concentration of about 1 mg / mL to about 2 mg / mL, at a pH of about 5.6.

[0924] Composition of matter

[0925] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, and having a G1F oligosaccharide content between about 15% and about 27%, wherein the drug substance is manufactured using a process comprising the steps of culturing a host cell comprising a polynucleotide encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, in a culture medium measured to contain about 8.5 ppb or less Mn, thereby producing a drug substance comprising an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0926] The present disclosure also provides a drug substance comprising an anti-CD38 antibody, the anti-CD38 antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of culturing CHO cells transfected with polynucleotides encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, in a culture medium comprising about 8.0 ppb or less Mn, thereby producing the drug substance.

[0927] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, and having a G1F oligosaccharide content between about 15% and about 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 8.5 ppb or less Mn; and culturing a host cell comprising a polynucleotide encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, in a culture medium comprising about 8.5 ppb or less Mn, thereby producing a drug substance comprising an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0928] The present disclosure also provides a drug substance comprising an anti-CD38 antibody, the anti-CD38 antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 8.0 ppb or less Mn; and culturing a host cell comprising a polynucleotide encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, in a culture medium comprising about 8.0 ppb or less Mn, thereby producing the drug substance.

[0929] In some embodiments, the anti-CD38 antibody comprises the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8, and the host cell comprises a polynucleotide encoding the VH of SEQ ID NO:7 and the VL of SEQ ID NO:8.

[0930] In some embodiments, the anti-CD38 antibody comprises the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10, and the host cell comprises a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10.

[0931] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 16% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 17% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 18% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 19% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 20% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%.

[0932] In some embodiments, the GOF content of the anti-CD38 antibody is between about 65% and about 74%.

[0933] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 66% and 74%. In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 67% and about 74%. In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%.

[0934] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising a VH of SEQ ID NO:7 and a VL of SEQ ID NO:8, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of culturing a host cell transfected with a polynucleotide encoding a VH of SEQ ID NO:7 and a VL of SEQ ID NO:8 in a culture medium measured to contain about 8.5 ppb or less Mn, thereby producing a drug substance comprising an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0935] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising VH of SEQ ID NO:7 and VL of SEQ ID NO:8, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 8.0 ppb or less Mn; and culturing a host cell comprising a polynucleotide encoding VH of SEQ ID NO:7 and VL of SEQ ID NO:8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing the drug substance.

[0936] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8, and having a G1F oligosaccharide content between about 15% and about 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 8.5 ppb or less Mn; and culturing a host cell transfected with a polynucleotide encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing a drug substance comprising an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0937] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8, respectively, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 8.0 ppb or less Mn; and culturing a host cell comprising a polynucleotide encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising about 8.0 ppb or less Mn, thereby producing the drug substance.

[0938] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of culturing a host cell transfected with a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium measured to contain about 8.5 ppb or less Mn, thereby producing a drug substance comprising an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0939] The present disclosure also provides a drug substance comprising an anti-CD38 antibody, the anti-CD38 antibody comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the following steps: culturing CHO cells transfected with a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium comprising about 8.0 ppb or less Mn, thereby producing the drug substance.

[0940] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 8.5 ppb or less Mn; and culturing a host cell transfected with a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium comprising about 8.5 ppb or less Mn, thereby producing a drug substance comprising an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0941] The present disclosure also provides a drug substance comprising an anti-CD38 antibody, the anti-CD38 antibody comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 8.0 ppb or less Mn; and culturing a host cell comprising a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium comprising about 6.5 ppb or less Mn, thereby producing the drug substance.

[0942] The present disclosure also provides a drug substance comprising an anti-CD38 antibody, the anti-CD38 antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of culturing CHO cells transfected with polynucleotides encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, in a culture medium comprising about 6.5 ppb or less Mn, thereby producing the drug substance.

[0943] The present disclosure also provides a drug substance comprising an anti-CD38 antibody, the anti-CD38 antibody comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 6.5 ppb or less Mn; and culturing a host cell transfected with a polynucleotide encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, in a culture medium comprising about 6.5 ppb or less Mn, thereby producing the drug substance.

[0944] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8, respectively, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the following steps: culturing CHO cells transfected with polynucleotides encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising about 6.5 ppb or less Mn, thereby producing the drug substance.

[0945] The present disclosure also provides a drug substance comprising an anti-CD38 antibody comprising VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8, respectively, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 6.5 ppb or less Mn; and culturing a host cell transfected with a polynucleotide encoding VH of SEQ ID NO: 7 and VL of SEQ ID NO: 8 in a culture medium comprising about 6.5 ppb or less Mn, thereby producing the drug substance.

[0946] The present disclosure also provides a drug substance comprising an anti-CD38 antibody, the anti-CD38 antibody comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the following steps: culturing CHO cells transfected with a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium comprising about 6.5 ppb or less Mn, thereby producing the drug substance.

[0947] The present disclosure also provides a drug substance comprising an anti-CD38 antibody, the anti-CD38 antibody comprising the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10, and having a G1F oligosaccharide content between about 15% and 27%, wherein the drug substance is manufactured using a process comprising the steps of: preparing a culture medium comprising about 6.5 ppb or less Mn; and culturing a host cell transfected with a polynucleotide encoding the HC of SEQ ID NO:9 and the LC of SEQ ID NO:10 in a culture medium comprising about 6.5 ppb or less Mn, thereby producing the drug substance.

[0948] In some embodiments, the culture medium is prepared by measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting to prepare the culture medium those batches of raw material components that, when combined, contain about 8.5 ppb or less Mn.

[0949] In some embodiments, the culture medium is prepared by measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting to prepare the culture medium those batches of raw material components that, when combined, contain about 8.0 ppb or less Mn.

[0950] In some embodiments, the culture medium comprises about 8.0 ppb, about 7.5 ppb or less, about 7.0 ppb or less, about 6.5 ppb or less, about 6.0 ppb or less, about 5.5 ppb or less, or about 5.0 ppb or less Mn.

[0951] In some embodiments, the culture medium comprises about 8.0 ppb or less Mn.

[0952] In some embodiments, the culture medium comprises about 7.5 ppb or less Mn.

[0953] In some embodiments, the culture medium comprises about 7.0 ppb or less Mn.

[0954] In some embodiments, the culture medium comprises about 6.5 ppb or less Mn.

[0955] In some embodiments, the culture medium comprises about 6.0 ppb or less Mn.

[0956] In some embodiments, the culture medium comprises about 5.5 ppb or less Mn.

[0957] In some embodiments, the culture medium comprises about 5.0 ppb or less Mn.

[0958] In some embodiments, the culture medium comprises between about 2 ppb and about 8.0 ppb Mn.

[0959] In some embodiments, the culture medium comprises between about 2 ppb and about 6.5 ppb Mn.

[0960] In some embodiments, the culture medium comprises between about 5.0 ppb and about 8.0 ppb Mn.

[0961] In some embodiments, the culture medium comprises between about 5.0 ppb and about 7.5 ppb Mn.

[0962] In some embodiments, the culture medium comprises between about 5.0 ppb and about 7.0 ppb Mn.

[0963] In some embodiments, the culture medium comprises between about 5.0 ppb and about 6.5 ppb Mn.

[0964] In some embodiments, the culture medium is a basal medium or a feed medium. In some embodiments, the culture medium is a basal medium. In some embodiments, the culture medium is a feed medium.

[0965] In some embodiments, the culture is a fed-batch culture. In some embodiments, the culture is a perfusion culture.

[0966] In some embodiments, the host cell is a eukaryotic cell.

[0967] In some embodiments, the eukaryotic cell is a CHO cell, a PER.C6 cell, a NS0 cell, a Sp2 / 0 cell, or a BHK cell.

[0968] In some embodiments, the CHO cells lack glutamine synthetase (GS).

[0969] In some embodiments, the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell, or a CHO-DXB11 cell.

[0970] In some embodiments, the drug substance is manufactured under GMP conditions.

[0971] The present disclosure also provides a pharmaceutical product produced by the method of the present disclosure.

[0972] The present disclosure also provides a pharmaceutical product comprising the drug substance of the present disclosure.

[0973] The present disclosure also provides a pharmaceutical product comprising an anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%, wherein the anti-CD38 antibody is produced by a process comprising the steps of culturing a host cell comprising a polynucleotide encoding the anti-CD38 antibody in a culture medium measured to contain about 8.5 ppb or less Mn, thereby producing the anti-CD38 antibody having a G1F oligosaccharide content between about 15% and about 27%.

[0974] In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 16% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 17% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 18% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 19% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 20% and about 26%. In some embodiments, the G1F oligosaccharide content of the anti-CD38 antibody is between about 21% and about 25%.

[0975] In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 65% and about 74%. In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 66% and 74%. In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 67% and about 74%. In some embodiments, the G0F oligosaccharide content of the anti-CD38 antibody is between about 68% and about 74%.

[0976] In some embodiments, the culture medium is prepared by measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting to prepare the culture medium those batches of raw material components that, when combined, contain about 8.5 ppb or less Mn.

[0977] In some embodiments, the culture medium comprises about 8.0 ppb, about 7.5 ppb or less, about 7.0 ppb or less, about 6.5 ppb or less, about 6.0 ppb or less, about 5.5 ppb or less, or about 5.0 ppb or less Mn.

[0978] In some embodiments, the culture medium comprises about 8.0 ppb or less Mn.

[0979] In some embodiments, the culture medium comprises about 7.5 ppb or less Mn.

[0980] In some embodiments, the culture medium comprises about 7.0 ppb or less Mn.

[0981] In some embodiments, the culture medium comprises about 6.5 ppb or less Mn.

[0982] In some embodiments, the culture medium comprises about 6.0 ppb or less Mn.

[0983] In some embodiments, the culture medium comprises about 5.5 ppb or less Mn.

[0984] In some embodiments, the culture medium comprises about 5.0 ppb or less Mn.

[0985] In some embodiments, the culture medium comprises between about 2 ppb and about 8.0 ppb Mn.

[0986] In some embodiments, the culture medium comprises between about 2 ppb and about 6.5 ppb Mn.

[0987] In some embodiments, the culture medium comprises between about 5.0 ppb and about 8.0 ppb manganese.

[0988] In some embodiments, the culture medium comprises between about 5.0 ppb and about 7.5 ppb manganese.

[0989] In some embodiments, the culture medium comprises between about 5.0 ppb and about 7.0 ppb manganese.

[0990] In some embodiments, the culture medium comprises between about 5.0 ppb and about 6.5 ppb manganese.

[0991] In some embodiments, the culture medium is a basal medium or a feed medium. In some embodiments, the culture medium is a basal medium. In some embodiments, the culture medium is a feed medium.

[0992] In some embodiments, the culture is a fed-batch culture. In some embodiments, the culture is a perfusion culture.

[0993] In some embodiments, the host cell is a eukaryotic cell.

[0994] In some embodiments, the eukaryotic cell is a CHO cell, a PER.C6 cell, a NS0 cell, a Sp2 / 0 cell, or a BHK cell.

[0995] In some embodiments, the CHO cells lack glutamine synthetase (GS).

[0996] In some embodiments, the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell, or a CHO-DXB11 cell.

[0997] In some embodiments, the drug product is manufactured under GMP conditions.

[0998] In some embodiments, the drug product comprises an anti-CD38 antibody having HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively.

[0999] In some embodiments, the drug product comprises an anti-CD38 antibody having a VH of SEQ ID NO:7 and a VL of SEQ ID NO:8.

[1000] In some embodiments, the drug product comprises an anti-CD38 antibody having a HC of SEQ ID NO:9 and a LC of SEQ ID NO:10.

[1001] In some embodiments, the drug product is a reference product.

[1002] In some embodiments, the drug product is a biosimilar.

[1003] In some embodiments, the drug product is (daratumumab) biosimilars.

[1004] In some embodiments, the drug product comprises about 20 mg / ml of an anti-CD38 antibody formulated in about 25 mM acetic acid, about 60 mM sodium chloride, about 140 mM mannitol, and about 0.04% w / v polysorbate-20 (PS-20); pH is about 5.5.

[1005] In some embodiments, the drug product comprises about 20 mg / mL to about 180 mg / mL of an anti-CD38 antibody and an amount of about 30,000 U to about 45,000 U of recombinant human hyaluronidase (rHuPH20).

[1006] In some embodiments, the drug product comprises about 1 mg / mL to about 180 mg / mL of the anti-CD38 antibody.

[1007] In some embodiments, the drug product comprises about 10 mg / mL to about 180 mg / mL of the anti-CD38 antibody.

[1008] In some embodiments, the drug product comprises about 20 mg / mL to about 160 mg / mL of the anti-CD38 antibody.

[1009] In some embodiments, the drug product comprises about 20 mg / mL to about 140 mg / mL of the anti-CD38 antibody.

[1010] In some embodiments, the drug product comprises about 20 mg / mL to about 120 mg / mL of the anti-CD38 antibody.

[1011] In some embodiments, the drug product comprises about 40 mg / mL to about 120 mg / mL of the anti-CD38 antibody.

[1012] In some embodiments, the drug product comprises about 60 mg / mL to about 120 mg / mL of the anti-CD38 antibody.

[1013] In some embodiments, the drug product comprises about 80 mg / mL to about 120 mg / mL of the anti-CD38 antibody.

[1014] In some embodiments, the drug product comprises about 100 mg / mL to about 120 mg / mL of the anti-CD38 antibody.

[1015] In some embodiments, the drug product comprises about 1 mg / mL, about 5 mg / mL, about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, about 60 mg / mL, about 70 mg / mL, about 80 mg / mL, about 90 mg / mL, about 100 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, or about 180 mg / mL of an anti-CD38 antibody.

[1016] In some embodiments, the drug product comprises about 20 mg / mL of the anti-CD38 antibody.

[1017] In some embodiments, the drug product comprises about 100 mg / mL of the anti-CD38 antibody.

[1018] In some embodiments, the drug product comprises about 120 mg / mL of the anti-CD38 antibody.

[1019] In some embodiments, the drug product comprises about 50 U / mL to about 5,000 U / mL of rHuPH20.

[1020] In some embodiments, the drug product comprises about 500 U / mL to about 5,000 U / mL of rHuPH20.

[1021] In some embodiments, the drug product comprises about 1,000 U / mL to about 5,000 U / mL of rHuPH20.

[1022] In some embodiments, the drug product comprises about 2,000 U / mL to about 5,000 U / mL of rHuPH20.

[1023] In some embodiments, the drug product comprises about 50 U / mL to about 2,000 U / mL of rHuPH20.

[1024] In some embodiments, the drug product comprises about 500 U / mL to about 2,00...

Claims

1. A method for producing an anti-CD38 antibody, the anti-CD38 antibody being expressed by a polynucleotide encoding a heavy chain variable region (VH) of SEQ ID NO: 7 and a light chain variable region (VL) of SEQ ID NO: 8 and having a G1F oligosaccharide content between 15% and 27%, the method comprising: a) preparing a culture medium comprising 2 parts per billion (ppb) to 8.5 ppb manganese (Mn); as well as b) controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing the host cell comprising the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in the culture medium prepared in step a), thereby producing the anti-CD38 antibody expressed by the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having the G1F oligosaccharide content between 15% and 27%, The host cell is a CHO cell. 2 . The method of claim 1 , wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 25%.

3. The method of claim 1, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 21% and 25%.

4. The method according to any one of claims 1 to 3, wherein the anti-CD38 antibody has a G0F oligosaccharide content between 65% and 74%.

5. The method according to any one of claims 1 to 3, wherein the anti-CD38 antibody has a G0F oligosaccharide content between 68% and 74%.

6. The method of any one of claims 1 to 3, wherein preparing the culture medium comprises measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting the one or more batches of raw material components that, when combined, contain 2 ppb to 8.5 ppb.

7. The method of claim 6, wherein the culture medium is prepared to contain between 4.0 ppb and 8.5 ppb Mn.

8. The method of claim 7, wherein the culture medium is prepared to contain between 4.0 ppb and 6.5 ppb Mn.

9. The method of claim 8, wherein the culture medium is prepared to contain between 5.0 ppb and 6.5 ppb Mn.

10. The method of claim 1, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 27%, the G0F oligosaccharide content of the anti-CD38 antibody is between 65% and 74%, and the culture medium is prepared to contain between 4.0 ppb and 8.5 ppb Mn.

11. The method of claim 1, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between 68% and 74%, and the culture medium is prepared to contain between 4.0 ppb and 6.5 ppb Mn.

12. The method of claim 1, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 21% and 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between 68% and 74%, and the culture medium is prepared to contain between 5.0 ppb and 6.5 ppb Mn.

13. The method according to any one of claims 1 to 3 and 10 to 12, wherein the culture medium is a basal medium or a feed medium.

14. The method according to any one of claims 1 to 3 and 10 to 12, wherein the culturing comprises fed-batch culturing or perfusion culturing.

15. The method according to any one of claims 1 to 3 and 10 to 12, wherein the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell or a CHO-DXB11 cell.

16. The method of claim 15, wherein the CHO cells lack glutamine synthetase (GS).

17. The method according to any one of claims 1 to 3 and 10 to 12, wherein the method is carried out under conditions that comply with GMP.

18. The method of any one of claims 1 to 3 and 10 to 12, wherein the anti-CD38 antibody comprises an IgG1 isotype.

19. The method of any one of claims 1 to 3 and 10 to 12, wherein the anti-CD38 antibody comprises a heavy chain (HC) of SEQ ID NO: 9 and a light chain (LC) of SEQ ID NO:

10.

20. The method of any one of claims 1 to 3 and 10 to 12, wherein the anti-CD38 antibody is a biosimilar.

21. A method for producing an anti-CD38 antibody expressed by a polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between 15% and 27%, the method comprising: a) culturing a host cell expressing the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 under conditions where the anti-CD38 antibody is produced; and b) controlling the G1F oligosaccharide content of the anti-CD38 antibody by monitoring the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody and adjusting the concentration of Mn in the culture medium during the biosynthesis of the anti-CD38 antibody, wherein the concentration of Mn in the culture medium is adjusted to contain 2 ppb to 8.5 ppb Mn, thereby producing the anti-CD38 antibody having the G1F oligosaccharide content between 15% and 27%, The host cell is a CHO cell.

22. The method of claim 21, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 25%.

23. The method of claim 22, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 21% and 25%.

24. The method of claim 21, wherein the anti-CD38 antibody has a G0F oligosaccharide content between 65% and 74%.

25. The method of claim 22, wherein the anti-CD38 antibody has a G0F oligosaccharide content between 68% and 74%.

26. The method of claim 21, wherein the concentration of Mn in the culture medium is adjusted to contain between 4.0 ppb and 8.5 ppb Mn.

27. The method of claim 26, wherein the concentration of Mn in the culture medium is adjusted to contain between 4.0 ppb and 6.5 ppb Mn.

28. The method of claim 27, wherein the concentration of Mn in the culture medium is adjusted to contain between 5.0 ppb and 6.5 ppb Mn.

29. The method of claim 21, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 27%, the G0F oligosaccharide content of the anti-CD38 antibody is between 65% and 74%, and the culture medium is adjusted to contain between 4.0 ppb and 8.5 ppb Mn.

30. The method of claim 21, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between 68% and 74%, and the culture medium is adjusted to contain between 4.0 ppb and 6.5 ppb Mn.

31. The method of claim 21, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 21% and 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between 68% and 74%, and the culture medium is adjusted to contain between 5.0 ppb and 6.5 ppb Mn.

32. The method according to any one of claims 21 to 31, wherein the culture medium is a basal medium or a feed medium.

33. The method according to any one of claims 21 to 31, wherein the culturing comprises fed-batch culturing or perfusion culturing.

34. The method according to any one of claims 21 to 31, wherein the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell or a CHO-DXB11 cell.

35. The method of claim 34, wherein the CHO cells lack GS.

36. The method according to any one of claims 21 to 31, wherein the method is carried out under GMP-compliant conditions.

37. The method of any one of claims 21 to 31, wherein the anti-CD38 antibody comprises an IgGl isotype.

38. The method of any one of claims 21 to 31, wherein the anti-CD38 antibody comprises the HC of SEQ ID NO: 9 and the LC of SEQ ID NO:

10.

39. The method of any one of claims 21 to 31, wherein the anti-CD38 antibody is a biosimilar.

40. A method of producing a drug product comprising an anti-CD38 antibody expressed from polynucleotides encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 and having a G1F oligosaccharide content between 15% and 27%, the method comprising: a) preparing a culture medium comprising 2 ppb to 8.5 ppb Mn; b) controlling the G1F oligosaccharide content of the anti-CD38 antibody by culturing a host cell comprising the polynucleotide encoding the VH of SEQ ID NO: 7 and the VL of SEQ ID NO: 8 in the culture medium prepared in step a), thereby producing the anti-CD38 antibody having the G1F oligosaccharide content between 15% and 27%; and c) formulating the anti-CD38 antibody into a pharmaceutical product, The host cell is a CHO cell.

41. The method of claim 40, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 25%.

42. The method of claim 41, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 21% and 25%.

43. The method of any one of claims 40-42, wherein the anti-CD38 antibody has a G0F oligosaccharide content between 65% and 74%.

44. The method of any one of claims 40-42, wherein the anti-CD38 antibody has a G0F oligosaccharide content between 68% and 74%.

45. The method of claim 40, wherein preparing the culture medium comprises measuring the Mn concentration in one or more batches of raw material components used to prepare the culture medium and selecting those one or more batches of raw material components that, when combined, contain 2 ppb to 8.5 ppb Mn.

46. ​​The method of claim 45, wherein the culture medium is prepared to contain between 4.0 ppb and 8.5 ppb Mn.

47. The method of claim 46, wherein the culture medium is prepared to contain between 4.0 ppb and 6.5 ppb Mn.

48. The method of claim 47, wherein the culture medium is prepared to contain between 5.0 ppb and 6.5 ppb Mn.

49. The method of claim 40, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 27%, the G0F oligosaccharide content of the anti-CD38 antibody is between 65% and 74%, and the culture medium is prepared to contain between 4.0 ppb and 8.5 ppb Mn.

50. The method of claim 40, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 15% and 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between 68% and 74%, and the culture medium is prepared to contain between 4.0 ppb and 6.5 ppb Mn.

51. The method of claim 40, wherein the G1F oligosaccharide content of the anti-CD38 antibody is between 21% and 25%, the G0F oligosaccharide content of the anti-CD38 antibody is between 68% and 74%, and the culture medium is prepared to contain between 5.0 ppb and 6.5 ppb Mn.

52. The method according to any one of claims 40 to 42 and 45 to 51, wherein the culture medium is a basal medium or a feed medium.

53. The method of any one of claims 40 to 42 and 45 to 51, wherein culturing comprises fed-batch culturing or perfusion culturing.

54. The method of any one of claims 40 to 42 and 45 to 51, wherein the CHO cell is a CHO-K1 cell, a CHO-DG44 cell, a CHO-S cell or a CHO-DXB11 cell.

55. The method of claim 54, wherein the CHO cells lack glutamine synthetase (GS).

56. The method according to any one of claims 40 to 42 and 45 to 51, wherein the method is carried out under GMP-compliant conditions.

57. The method of any one of claims 40 to 42 and 45 to 51, wherein the anti-CD38 antibody comprises an IgG1 isotype.

58. The method of any one of claims 40 to 42 and 45 to 51, wherein the anti-CD38 antibody comprises the HC of SEQ ID NO: 9 and the LC of SEQ ID NO:

10.

59. The method of any one of claims 40 to 42 and 45 to 51, wherein the anti-CD38 antibody is a biosimilar.

60. The method of any one of claims 40 to 42 and 45 to 51, wherein formulating the drug product comprises formulating 20 mg / mL to 180 mg / mL of the anti-CD38 antibody using 30,000 U to 45,000 U of recombinant human hyaluronidase (rHuPH20), 5 mM to 15 mM of histidine, 100 mM to 300 mM of sorbitol, 0.01% w / v to 0.04% w / v of PS-20, and 1 mg / mL to 2 mg / mL of methionine, at a pH of 5.

6.

61. The method of any one of claims 40 to 42 and 45 to 51, wherein formulating the drug product comprises formulating 120 mg / mL of the anti-CD38 antibody in 2,000 U / ml recombinant human hyaluronidase (rHuPH20), 5 mM to 15 mM histidine, 100 mM to 300 mM sorbitol, 0.01% w / v to 0.04% w / v PS-20, and 1 mg / mL to 2 mg / mL methionine, at a pH of 5.

6.

62. The method of any one of claims 40 to 42 and 45 to 51, wherein formulating the drug product comprises formulating 20 mg / ml of the anti-CD38 antibody in 25 mM acetic acid, 60 mM sodium chloride, 140 mM mannitol, and 0.04% w / v polysorbate-20 (PS-20); pH 5.5.